Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

109.86 +2.92 (+2.73%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Investors seeking growth at a reasonable cost should explore NASDAQ:HALO. ↗

November 01, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is showing good growth, while it is not too expensive.

Via Chartmill

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 31, 2024

Via Benzinga

Investors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents. ↗

October 31, 2024

For those who appreciate value investing, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a compelling option with its solid fundamentals.

Via Chartmill

A Look Ahead: Halozyme Therapeutics's Earnings Forecast ↗

October 30, 2024

Via Benzinga

Unveiling 12 Analyst Insights On Halozyme Therapeutics ↗

October 25, 2024

Via Benzinga

Exploring the Growth Potential of NASDAQ:HALO as It Nears a Breakout. ↗

October 22, 2024

Exploring the Growth Potential of HALOZYME THERAPEUTICS INC (NASDAQ:HALO) as It Nears a Breakout.

Via Chartmill

Despite its growth, NASDAQ:HALO remains within the realm of affordability. ↗

October 11, 2024

Despite its growth, NASDAQ:HALO remains within the realm of affordability.

Via Chartmill

Despite its impressive fundamentals, NASDAQ:HALO remains undervalued. ↗

October 10, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals.

Via Chartmill

(HALO) - Analyzing Halozyme Therapeutics's Short Interest ↗

September 13, 2024

Via Benzinga

A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 12 Analysts ↗

October 04, 2024

Via Benzinga

NASDAQ:HALO is showing good growth, while it is not too expensive. ↗

September 19, 2024

Investors should take note ofHALOZYME THERAPEUTICS INC (NASDAQ:HALO), a growth stock that remains attractively priced.

Via Chartmill

NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

September 19, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) appears to be flying under the radar despite its strong fundamentals.

Via Chartmill

Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm

September 17, 2024

From Kaskela Law LLC

Via Business Wire

Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

September 13, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.

Via Chartmill

Critical Insights From Halozyme Therapeutics Analyst Ratings: What You Need To Know ↗

September 13, 2024

Via Benzinga

NASDAQ:HALO is not too expensive for the growth it is showing. ↗

August 29, 2024

NASDAQ:HALO is showing good growth, while it is not too expensive.

Via Chartmill

Top 2 Health Care Stocks That May Plunge In August ↗

August 26, 2024

Via Benzinga

How Is The Market Feeling About Halozyme Therapeutics? ↗

August 20, 2024

Via Benzinga

NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

August 28, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO): good value for what you're paying.

Via Chartmill

Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review ↗

August 09, 2024

After Monday's panicked global sell-off, markets have calmed down.

Via Investor's Business Daily

Looking for growth without the hefty price tag? Consider NASDAQ:HALO. ↗

August 08, 2024

Investors should take note ofHALOZYME THERAPEUTICS INC (NASDAQ:HALO), a growth stock that remains attractively priced.

Via Chartmill

Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

August 08, 2024

Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation.

Via Chartmill

HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗

August 06, 2024

HALO stock results show that Halozyme Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

(HALO) - Analyzing Halozyme Therapeutics's Short Interest ↗

August 01, 2024

Via Benzinga

Analyst Scoreboard: 14 Ratings For Halozyme Therapeutics ↗

August 01, 2024

Via Benzinga

Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts ↗

August 06, 2024

Halozyme and Ligand beat second-quarter expectations late Tuesday. But only one of the biotech stocks jumped.

Via Investor's Business Daily

Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82 ↗

August 06, 2024

On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82.

Via Investor's Business Daily

NASDAQ:HALO is probably undervalued for the fundamentals it is displaying. ↗

August 05, 2024

When you look at HALOZYME THERAPEUTICS INC (NASDAQ:HALO), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

Via Chartmill

3 Biotech Stocks on Track for 50% Returns (or More) by 2028 ↗

August 04, 2024

Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028!

Via InvestorPlace

Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark ↗

July 26, 2024

On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.